Abstract
BackgroundSynovial sarcoma (SS) is a type of soft tissue sarcoma (STS) of undetermined tissue origin, which is characterized by the recurrent pathognomonic chromosomal translocation t (X;18)(p11.2; q11.2). Studies have shown that SS is a malignant tumor originating from cancer stem cells or pluripotent mesenchymal stem cells and may be related to fusion genes. In addition, some studies have indicated that the induction of epithelial–mesenchymal transition (EMT) via the TGF-β1/Smad signaling pathway leads to SS metastasis.MethodsWe analyzed the effects of SYT-SSX1 on the stemness of SS cells via TGF-β1/Smad signaling in vitro. The SYT-SSX1 fusion gene high expression cell was constructed by lentiviral stable transfer technology. SYT-SSX1 and SW982 cells were cultured and tested for sphere-forming ability. The transwell migration assay and flow cytometry were used to assess the migration ability of the sphere cells as well as the expression of CSC-related markers. We treated SYT-SSX1 cells with rhTGF-β1 (a recombinant agent of the TGF-β1 signaling pathway) and SB431542 and observed morphological changes. A CCK-8 experiment and a western blot (WB) experiment were conducted to detect the expression of TGF-β1 signaling pathway- and EMT-related proteins after treatment. The SYT-SSX1 cells were then cultured and their ability to form spheres was tested. Flow cytometry, WB, and quantitative real-time polymerase chain reaction (qRT-PCR) were used to detect the expression of CSC surface markers on SYT-SSX1 sphere cells.ResultsIt was found that SYT-SSX1 has stronger sphere-forming ability, migration ability, and higher expression of CSC-related molecules than SW982 cells. Through treating SYT-SSX1 and SW982 cells with rhTGF-β1 and SB431542, we found that TGF-β1 enhanced the proliferation of cells, induced EMT, and that TGF-β1 enhanced the characteristics of tumor stem cells.ConclusionsOur results suggest that SYT-SSX1 enhances invasiveness and maintains stemness in SS cells via TGF-β1/Smad signaling. These findings reveal an effective way to potentially improve the prognosis of patients with SS by eliminating the characteristics of cancer stem cells (CSCs) during treatment.
Highlights
Synovial sarcoma (SS) is a type of soft tissue sarcoma (STS) of undetermined tissue origin, which is char‐ acterized by the recurrent pathognomonic chromosomal translocation t (X;18)(p11.2; q11.2)
Qi et al BMC Cancer (2022) 22:166 we found that TGF-β1 enhanced the proliferation of cells, induced epithelial–mesenchymal transition (EMT), and that TGF-β1 enhanced the characteristics of tumor stem cells
Our results suggest that SYT-SSX1 enhances invasiveness and maintains stemness in SS cells via TGFβ1/Smad signaling
Summary
Synovial sarcoma (SS) is a type of soft tissue sarcoma (STS) of undetermined tissue origin, which is char‐ acterized by the recurrent pathognomonic chromosomal translocation t (X;18)(p11.2; q11.2). Studies have shown that SS is a malignant tumor originating from cancer stem cells or pluripotent mesenchymal stem cells and may be related to fusion genes. Synovial sarcoma (SS) is a highly aggressive malignant tumor of mesenchymal origin and is the fourth most common type of soft tissue sarcoma (STS), accounting for approximately 5–10% of all STSs [1]. Recent studies have shown that SS may originate from cancer stem cells (CSCs) or pluripotent mesenchymal stem cells [2, 3]. Surgical resection is the first choice for treatment followed by postoperative adjuvant radiotherapy and chemotherapy [5, 6]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
